Alice Guilleux1,2, Jonathan Roux1, David Travers3, Emmanuelle Leray1,2. 1. EHESP, REPERES, University of Rennes, France. 2. Centre d'Investigation Clinique de Rennes, University of Rennes, France. 3. Department of Psychiatry, University Hospital CHU Pontchaillou, France.
Abstract
BACKGROUND: Mental disorders (MDs) in multiple sclerosis (MS) patients decreases treatment adherence and quality of life, and increases the risk of disability progression and care consumption. OBJECTIVE: This study was to assess the prevalence of MDs in MS patients compared with healthy controls (HC) of the French general population and rheumatoid arthritis (RA) patients. METHODS: The 2015 prevalence of MDs for MS patients, RA patients and general population was estimated using a random population-based data sample from 'National Inter-Scheme Information System on Health Insurance' in the 2011-2015 period. Two control groups (1:5 ratio for the HC and 1:1 for the RA group) were matched to the MS group for year of birth, gender, area of residence and health insurance scheme. RESULTS: A total of 1145 MS patients were identified (sex ratio of 2.5 (F/M); median age 50 years). The prevalence of MDs was higher in the population of patients with MS (37.3%) than in the French general population (13.6%), and to a lesser extent in the RA group (21.1%) leading to the prevalence ratios of 2.8 (95% confidence intervals (CIs) 2.5-3.0) and 1.9 (95% CI 1.7-2.3), respectively. CONCLUSIONS: This study confirmed that MS patients are at a higher risk of MDs than the French general population or RA patients.
BACKGROUND: Mental disorders (MDs) in multiple sclerosis (MS) patients decreases treatment adherence and quality of life, and increases the risk of disability progression and care consumption. OBJECTIVE: This study was to assess the prevalence of MDs in MS patients compared with healthy controls (HC) of the French general population and rheumatoid arthritis (RA) patients. METHODS: The 2015 prevalence of MDs for MS patients, RA patients and general population was estimated using a random population-based data sample from 'National Inter-Scheme Information System on Health Insurance' in the 2011-2015 period. Two control groups (1:5 ratio for the HC and 1:1 for the RA group) were matched to the MS group for year of birth, gender, area of residence and health insurance scheme. RESULTS: A total of 1145 MS patients were identified (sex ratio of 2.5 (F/M); median age 50 years). The prevalence of MDs was higher in the population of patients with MS (37.3%) than in the French general population (13.6%), and to a lesser extent in the RA group (21.1%) leading to the prevalence ratios of 2.8 (95% confidence intervals (CIs) 2.5-3.0) and 1.9 (95% CI 1.7-2.3), respectively. CONCLUSIONS: This study confirmed that MS patients are at a higher risk of MDs than the French general population or RA patients.
Authors: Julien Bezin; Mai Duong; Régis Lassalle; Cécile Droz; Antoine Pariente; Patrick Blin; Nicholas Moore Journal: Pharmacoepidemiol Drug Saf Date: 2017-05-24 Impact factor: 2.890
Authors: Kyla A McKay; Helen Tremlett; John D Fisk; Tingting Zhang; Scott B Patten; Lorne Kastrukoff; Trudy Campbell; Ruth Ann Marrie Journal: Neurology Date: 2018-03-09 Impact factor: 9.910
Authors: A C J W Janssens; P A van Doorn; J B de Boer; N F Kalkers; F G A van der Meche; J Passchier; R Q Hintzen Journal: Mult Scler Date: 2003-08 Impact factor: 6.312
Authors: Ruth Ann Marrie; John D Fisk; Helen Tremlett; Christina Wolfson; Sharon Warren; Aruni Tennakoon; Stella Leung; Scott B Patten Journal: Neurology Date: 2015-10-30 Impact factor: 9.910